Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.31 |
| ▸ | PDE2A | O00408 | 2/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963139 | 1.00 | CDC7 (0.42) | CDC7CDK2MCL1HTR7S1PR1 | |
| SCHEMBL964913 | 0.86 | CDC7 (0.43) | CDC7CDK2MCL1HTR7S1PR1 | |
| SCHEMBL968527 | 0.85 | CDC7 (0.38) | CDC7CDK2 | |
| SCHEMBL968529 | 0.85 | CDC7 (0.38) | CDC7CDK2 | |
| SCHEMBL964457 | 0.84 | ALDH1A1 (0.43) | CDC7CDK2MCL1 | |
| SCHEMBL964456 | 0.84 | ALDH1A1 (0.43) | CDC7CDK2MCL1 | |
| SCHEMBL964712 | 0.83 | CA2 (0.46) | — | |
| SCHEMBL964576 | 0.83 | CA2 (0.46) | — | |
| SCHEMBL963832 | 0.82 | ALDH1A1 (0.34) | MCL1PTGS2PDE10APTGS1 | |
| SCHEMBL963829 | 0.82 | ALDH1A1 (0.34) | MCL1PTGS2PDE10APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | CDC7 2245/4885CDK2 2555/4885MCL1 3194/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | CDC7 4163/4885CDK2 2985/4885MCL1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.